Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater

被引：0

作者：

Tambo, Yuichi ^{[1
]}

Sone, Takashi ^{[1
]}

Shibata, Kazuhiko ^{[2
]}

Nishi, Kouichi ^{[3
]}

Shirasaki, Hiroki ^{[4
]}

Yoneda, Taro ^{[5
]}

Araya, Tomoyuki ^{[6
]}

Kase, Kazumasa ^{[7
]}

Nishikawa, Shingo ^{[1
]}

Kimura, Hideharu ^{[1
]}

Kasahara, Kazuo ^{[1
]}

机构：

[1] Kanazawa Univ Hosp, Resp Med, Kanazawa, Ishikawa, Japan

[2] Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan

[3] Ishikawa Prefectural Cent Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan

[4] Fukui Ken Saiseikai Hosp, Dept Resp Med, Fukui, Japan

[5] Komatsu Municipal Hosp, Dept Resp Med, Komatsu, Japan

[6] Natl Hosp Org Kanazawa Med Ctr, Dept Resp Med, Kanazawa, Ishikawa, Japan

[7] Keiju Med Ctr, Dept Internal Med, Nanao, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.626

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO25-3

引用

页码：S313 / S313

页数：1

共 50 条

[41] First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
Robinson, A. G.
Vicente, D.
Tafreshi, A.
Parra, H. Soto
Mazieres, J.
Cicin, I.
Medgyasszay, B.
Rodriguez-Cid, J.
Okamoto, I.
Lee, S.
Ramlau, R.
Vladimirov, V.
Cheng, Y.
Halmos, B.
Liu, C-C.
Schwarzenberger, P.
Piperdi, B.
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S748 - S749
[42] Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
Rittberg, Rebekah
Leung, Bonnie
Shokoohi, Aria
Pender, Alexandra
Wong, Selina
Al-Hashami, Zamzam
Wang, Ying
Ho, Cheryl
CURRENT ONCOLOGY, 2023, 30 (06) : 5299 - 5308
[43] Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC
Xu, Yingqi
Zhang, Yidan
Qiang, Huiping
Zhong, Hua
Xu, Jianlin
Zhong, Runbo
LUNG CANCER, 2024, 194
[44] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
Chen, Ya
Wang, Yanan
Yang, Zhengyu
Hu, Minjuan
Zhang, Yanwei
Qian, Fangfei
Zhang, Wei
Zhang, Bo
Han, Baohui
FRONTIERS IN ONCOLOGY, 2021, 11
[45] First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials
Doherty, M.
Delos Santos, S.
Rahmadian, A. Putri
Chan, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S465 - S466
[46] Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
Boyer, M.
Sendur, M. A. N.
Rodriguez-Abreu, D.
Park, K.
Lee, D. H.
Cicin, I.
Yumuk, P. F.
Orlandi, F.
Leal, T.
Molinier, O.
Soparattanapaisam, N.
Langleben, A.
Califano, R.
Medgyasszay, B.
Hsia, T.
Otterson, G.
Xu, L.
Piperdi, B.
Samkari, A.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S62
[47] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Zhou, Yixin
Lin, Zuan
Zhang, Xuanye
Chen, Chen
Zhao, Hongyun
Hong, Shaodong
Zhang, Li
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[48] Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Fiorelli, Alfonso
Vitiello, Fabiana
Morgillo, Floriana
Santagata, Mario
Spuntarelli, Chiara
Di Domenico, Marina
Santini, Mario
Bianco, Andrea
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S618 - S620
[49] Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial
Ren, S.
Wang, X.
Han, B.
Pan, Y.
Zhao, J.
Cheng, Y.
Hu, S.
Liu, T.
Li, Y.
Cheng, Y.
Feng, J.
Yi, S.
Gu, S.
Gao, S.
Luo, Y.
Liu, Y.
Liu, C.
Duan, H.
Zhou, C.
Fan, J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S66 - S67
[50] PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy
Reactions Weekly, 2023, 1980 (1) : 10 - 10

← 1 2 3 4 5 →